 The purpose of this study is to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis RRMS, and to characterize its safety and tolerability for the selection of an optimal dose in a later phase III study. 